Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...
FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a ...
Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta biosimilar to Accord BioPharma. About 50 employees who are associated with ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Intech Investment Management LLC bought a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with ...
Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback